Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary
BIOADAPTIVES, INC. (BDPT) reported a small net profit for the three and six months ended June 30, 2026, driven primarily by non‑cash derivative valuation gains rather than core operations. For the quarter, revenue was $4,988 with a gross profit of $4,240, while operating expenses of $201,416 produced an operating loss of $197,176.
Other income of $347,266, mainly a $446,730 gain from the change in fair value of derivative liabilities, led to quarterly net income of $150,090 (basic EPS $0.01). For the first half, revenue totaled $10,502, the operating loss was $395,394, and net income was $39,004 versus a $355,050 loss a year earlier.
The balance sheet remains highly stressed: total assets were only $78,767 against total liabilities of $1,844,874, including $1,050,397 of derivative liabilities and $490,629 of current convertible notes. Stockholders’ deficit was $1,766,107, with an accumulated deficit of $10,682,200. Management discloses substantial doubt about the company’s ability to continue as a going concern, cites material weaknesses in internal control, and notes defaults on legacy 12% debentures while seeking additional financing and relying on equity issuances.
Positive
- Swing to $39,004 net income for the six months ended June 30, 2026, from a $355,050 loss a year earlier, largely due to a $621,614 gain from changes in derivative liabilities.
- Derivative liabilities decreased to $1,050,397 from $1,738,804 at December 31, 2025, reflecting settlements and favorable fair value movements.
- Operating cash outflow improved to $129,224 for the first half of 2026 from $208,888 in the prior‑year period, indicating lower cash burn.
Negative
- Going concern uncertainty highlighted, with an accumulated deficit of $10,682,200 and reliance on future financing and equity issuances to sustain operations.
- Severe working capital deficit of $1,766,107 at June 30, 2026, with all $490,629 of convertible notes classified as current and cash of only $29,221.
- Material weaknesses in internal control over financial reporting disclosed, including inadequate segregation of duties and insufficient written accounting policies.
- Significant non‑operating risk from $1,050,397 of Level 3 derivative liabilities tied to highly dilutive convertible notes and warrants.
- Company is in default on legacy 12% debentures issued in 2018, with extensions expired and alternative resolutions still being negotiated.
